Lupin Launches Posaconazole Delayed-Release Tablets

▴ Lupin Launches Posaconazole Delayed-Release Tablets
Lupin & its AET Pharma US Inc. (part of Tiefenbacher Group) received an approval for its ANDA from the USFDA

Global pharma major Lupin Limited today announced the launch of Posaconazole Delayed-Release Tablets, 100 mg, after its alliance partner AET Pharma US Inc. (part of Tiefenbacher Group) received an approval for its ANDA from the United States Food and Drug Administration.

Posaconazole Delayed-Release Tablets, 100 mg, are the generic equivalent of Noxafil DelayedRelease Tablets, 100 mg, of Merck Sharp & Dohme Corp, and are indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. For the nine months ended December 31, 2020, the Company invested 9.8% of its revenues on research and development.

Tags : #LupinLtd #LatestNewsonLupinLtd17thFeb #LatestPharmaNews17thFeb #LatestUSFDAApproval17thFeb #AETPharmaUSInc #LatestMedicineforChemotherapy #CancerTreatment

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026
Fatty Liver Disease: Connecting Metabolic Health With Liver CareNovember 12, 2026
Chronic Kidney Disease: Understanding Risk Assessment and Early MonitoringNovember 12, 2026
Advanced OCTA Diagnostics in Age-Related Macular Degeneration (AMD)November 11, 2026
Advanced Diagnostics in Age-Related Macular Degeneration (AMD): Optical Coherence Tomography Angiography (OCTA)November 11, 2026
PCOS Care in India: Understanding Diagnosis and Long-Term MonitoringNovember 11, 2026
Thyroid Health: Making Sense of Testing and Follow-UpNovember 11, 2026
Advanced Navigation Systems in Neurosurgery: Precision TechNovember 11, 2026
Ambient Computing in Healthcare: India's Invisible Tech RevolutionNovember 11, 2026
World Diabetes Day 2026, ‘Early Action on Diabetes,’November 10, 2026
Gulf Medical University Celebrates 28 Years: Born in Thumbay, Built at GMUNovember 10, 2026
Patient Safety Is a Business Priority for Indian HospitalsNovember 10, 2026
Reducing ED Wait Times Through Smarter Hospital DesignNovember 10, 2026